Ali Aminian
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ali Aminian sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Ali Aminian: 4 sponsored US clinical trials, 2 recruiting.
Ali Aminian sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), with 1 trials.
Upper-quartile sponsor footprint
Ali Aminian sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
NCT06803888
Fibrosis Lessens After Metabolic Surgery
NCT06374875
Metabolic Surgery for Atrial Fibrillation Elimination
NCT07027969
Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes
NCT02328599
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 3 |
Where Ali Aminian enrollment is open (later-stage tilt)
2 recruiting of 4 indexed (50% open); 1 completed (25%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ali Aminian: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Ali Aminian sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Ali Aminian page
4 registered trials is a research-attention snapshot, not an endorsement of Ali Aminian or any single study.
- 2 of Ali Aminian's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the condition Ali Aminian studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ali Aminian pipeline card: 4 registered trials from official public datasets.Report a data error.